<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02729376</url>
  </required_header>
  <id_info>
    <org_study_id>TOK-200-18</org_study_id>
    <nct_id>NCT02729376</nct_id>
  </id_info>
  <brief_title>Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Galeterone</brief_title>
  <official_title>An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Galeterone in Healthy Male Subjects After Oral Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novus Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novus Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, single dose, 1 period study of [14C] galeterone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, 1 period study under fed conditions. Six (6), healthy, adult, non
      tobacco using, male subjects will be enrolled. Screening of subjects will occur within 28
      days prior to dosing. On Day 1, a single dose of radio-labeled galeterone will be
      administered orally. Blood, urine, and fecal samples will be collected until release criteria
      are met to measure total radioactivity, for analysis of galeterone concentrations, and for
      potential metabolic profiling.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radioactivity concentration equivalents in plasma</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single dose galeterone concentrations in plasma</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Route(s) of elimination of a single [14C]galeterone dose</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass balance of a single [14C]galeterone dose</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of whole blood to plasma 14C radioactivity</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single dose of [14C]-galeterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[14C]-galeterone will be supplied as 325 mg capsules (powder in capsule [PIC]). The treatment to be administered will be 2600 mg (~500 ÂµCi) (8 x 325 mg capsules).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>galeterone</intervention_name>
    <arm_group_label>Single dose of [14C]-galeterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy, adult, male, 19 to 55 years of age, inclusive, at screening.

          2. Continuous non smoker who has not used nicotine containing products for at least 3
             months prior to dosing.

          3. Understands the study procedures in the informed consent form (ICF), and be willing
             and able to comply with the protocol.

        Exclusion Criteria:

          1. History or presence of clinically significant medical or psychiatric condition or
             disease in the opinion of the PI.

          2. History of any illness that, in the opinion of the PI, might confound the results of
             the study or poses an additional risk to the subject by their participation in the
             study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen J Ferrante, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tokai Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2016</study_first_posted>
  <last_update_submitted>April 25, 2016</last_update_submitted>
  <last_update_submitted_qc>April 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

